Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Hemophilia Gene Therapy Market by Type (Hemophilia A, Hemophilia B, Hemophilia Gene Therap), By Application (Hemophilia A Gene Therapy, Hemophilia B Gene Therapy) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Hemophilia Gene Therapy Market by Type (Hemophilia A, Hemophilia B, Hemophilia Gene Therap), By Application (Hemophilia A Gene Therapy, Hemophilia B Gene Therapy) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 168211 3300 Medical Devices & Consumables 377 241 Pages 5 (46)
                                          

Market Overview:


The global hemophilia gene therapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of hemophilia, technological advancements in gene therapy, and rising investments by key players in this field. Hemophilia A is the most common type of hemophilia and accounts for approximately 80% of all cases. Hemophilia B is the second most common type and accounts for approximately 20% of all cases. North America dominates the global hemophilia gene therapy market, followed by Europe. The high prevalence of hemophilia in these regions drives the demand for novel therapies such as gene therapies.


Global Hemophilia Gene Therapy Industry Outlook


Product Definition:


Hemophilia gene therapy is a treatment that uses genes to fix or replace unhealthy or missing genes. This therapy can be used to treat diseases caused by a lack of certain proteins, including hemophilia.


Hemophilia A:


Hemophilia A is a rare genetic disorder caused by the lack of coagulation factor in the body. It’s primary symptom is bleeding into any part of the body, especially during exercise or injury. The other symptoms include easy bruising, nosebleed, frequent infections (more than average), and low platelet count leading to easy bleeding and pain when injured.


Hemophilia B:


Hemophilia B is a rare genetic disorder that affects the blood clotting mechanism. It is estimated that 1 in 5,000 babies are born with this condition every year. The disease mostly occurs among males and females carrying a defective gene for coagulation factor (F9).


The market size was valued at USD 2.8 billion in 2018 and is expected to register a CAGR of XX% over the forecast period.


Application Insights:


Based on application, the global market is segmented into hemophilia A gene therapy, hemophilia B gene therapy and other applications. The other applications include disorders of blood coagulation such as Christmas disease and Bleeding Disorder of uncertain significance (BSDOS). Hemophilia A held the largest share in terms of revenue in 2017 owing to availability of approved products for all three indications globally. Moreover, there are ongoing clinical trials for new drug development for various indications including hemophilia which is expected to propel growth over the forecast period.


Hemophilia B followed behind due to presence of only two approved products-Ferring Pharmaceuticals' Alprolix and Pfizer's Travenolone injection which were launched relatively late compared to their counterparts namely Ferring Pharmaceuticals' Feraheme and Janssen Sciences Ireland Ltd.'s Epzicom1/Ceravase1 respectively that were launched earlier.


Regional Analysis:


North America dominated the global market in 2017. This can be attributed to the presence of a substantial number of players, availability of advanced technologies and high awareness levels amongst people about this therapy. Moreover, approval and commercialization of products in this region are easier as compared to other regions due to higher healthcare infrastructure & development.


Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare facilities & infrastructure along with growing target population base in emerging countries such as China & India. Furthermore, increasing investments by governments for developing novel therapies will drive regional market growth during the forecast period.


Growth Factors:


  • Increasing incidence of hemophilia
  • Growing demand for gene therapy products
  • Rising awareness about hemophilia gene therapy treatments
  • Technological advancements in hemophilia gene therapy treatments
  • Availability of government funding for research and development of new hemophilia gene therapies

Scope Of The Report

Report Attributes

Report Details

Report Title

Hemophilia Gene Therapy Market Research Report

By Type

Hemophilia A, Hemophilia B, Hemophilia Gene Therap

By Application

Hemophilia A Gene Therapy, Hemophilia B Gene Therapy

By Companies

Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, Hemophilia Gene Therap

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

241

Number of Tables & Figures

169

Customization Available

Yes, the report can be customized as per your need.


Global Hemophilia Gene Therapy Market Report Segments:

The global Hemophilia Gene Therapy market is segmented on the basis of:

Types

Hemophilia A, Hemophilia B, Hemophilia Gene Therap

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hemophilia A Gene Therapy, Hemophilia B Gene Therapy

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Spark Therapeutics
  2. Ultragenyx
  3. Shire PLC
  4. Sangamo Therapeutics
  5. Bioverativ
  6. BioMarin
  7. uniQure
  8. Freeline Therapeutics
  9. Hemophilia Gene Therap

Global Hemophilia Gene Therapy Market Overview


Highlights of The Hemophilia Gene Therapy Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Hemophilia A
    2. Hemophilia B
    3. Hemophilia Gene Therap
  1. By Application:

    1. Hemophilia A Gene Therapy
    2. Hemophilia B Gene Therapy
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Hemophilia Gene Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Hemophilia Gene Therapy Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Hemophilia is a rare blood disorder that affects the ability of the blood to clot. Hemophilia A, which is the most common form of hemophilia, results when there is a deficiency or absence of one type of protein in the blood. Hemophilia B results from a deficiency or absence of another protein in the blood. Hemophilia C occurs when there is a combination of two different types of proteins that are needed for normal clotting.nnThere are currently three approved gene therapies for hemophiliacs: Factor VIII replacement therapy (FVIII), FIXation therapy (FIX), and rFVIIa treatment (rFIX). FVIII replacement therapy uses recombinant DNA technology to create an artificial version of factor VIII called humanized prokaryotic expression vector-derived factor VIII concentrate, or hPIVCu00ae . FIXation therapy uses recombinant DNA technology to create an artificial version as well as antibodies against FIX which bind and neutralize FIX activity inside cells so that they cannot cause bleeding episodes. rFIX treatment replaces defective fusions between chromosome 9 and chromosome 17 in people with hemophilia B, leading to improved bleeding control by promoting formation new clots outside affected cells instead

Some of the key players operating in the hemophilia gene therapy market are Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, Hemophilia Gene Therap.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Hemophilia Gene Therapy Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Hemophilia Gene Therapy Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Hemophilia Gene Therapy Market - Supply Chain
   4.5. Global Hemophilia Gene Therapy Market Forecast
      4.5.1. Hemophilia Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Hemophilia Gene Therapy Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Hemophilia Gene Therapy Market Absolute $ Opportunity

5. Global Hemophilia Gene Therapy Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Type
      5.3.1. Hemophilia A
      5.3.2. Hemophilia B
      5.3.3. Hemophilia Gene Therap
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Hemophilia Gene Therapy Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Application
      6.3.1. Hemophilia A Gene Therapy
      6.3.2. Hemophilia B Gene Therapy
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Hemophilia Gene Therapy Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Hemophilia Gene Therapy Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Hemophilia Gene Therapy Demand Share Forecast, 2019-2026

9. North America Hemophilia Gene Therapy Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Hemophilia Gene Therapy Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Hemophilia Gene Therapy Market Size and Volume Forecast by Application
      9.4.1. Hemophilia A Gene Therapy
      9.4.2. Hemophilia B Gene Therapy
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Hemophilia Gene Therapy Market Size and Volume Forecast by Type
      9.7.1. Hemophilia A
      9.7.2. Hemophilia B
      9.7.3. Hemophilia Gene Therap
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Hemophilia Gene Therapy Demand Share Forecast, 2019-2026

10. Latin America Hemophilia Gene Therapy Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Hemophilia Gene Therapy Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Hemophilia Gene Therapy Market Size and Volume Forecast by Application
      10.4.1. Hemophilia A Gene Therapy
      10.4.2. Hemophilia B Gene Therapy
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Hemophilia Gene Therapy Market Size and Volume Forecast by Type
      10.7.1. Hemophilia A
      10.7.2. Hemophilia B
      10.7.3. Hemophilia Gene Therap
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Hemophilia Gene Therapy Demand Share Forecast, 2019-2026

11. Europe Hemophilia Gene Therapy Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Hemophilia Gene Therapy Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Hemophilia Gene Therapy Market Size and Volume Forecast by Application
      11.4.1. Hemophilia A Gene Therapy
      11.4.2. Hemophilia B Gene Therapy
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Hemophilia Gene Therapy Market Size and Volume Forecast by Type
      11.7.1. Hemophilia A
      11.7.2. Hemophilia B
      11.7.3. Hemophilia Gene Therap
   11.8. Basis Point Share (BPS) Analysis by Type
   1.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Hemophilia Gene Therapy Demand Share, 2019-2026

12. Asia Pacific Hemophilia Gene Therapy Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Hemophilia Gene Therapy Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Hemophilia Gene Therapy Market Size and Volume Forecast by Application
      12.4.1. Hemophilia A Gene Therapy
      12.4.2. Hemophilia B Gene Therapy
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Hemophilia Gene Therapy Market Size and Volume Forecast by Type
      12.7.1. Hemophilia A
      12.7.2. Hemophilia B
      12.7.3. Hemophilia Gene Therap
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Hemophilia Gene Therapy Demand Share, 2019-2026

13. Middle East & Africa Hemophilia Gene Therapy Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Hemophilia Gene Therapy Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Hemophilia Gene Therapy Market Size and Volume Forecast by Application
      13.4.1. Hemophilia A Gene Therapy
      13.4.2. Hemophilia B Gene Therapy
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Hemophilia Gene Therapy Market Size and Volume Forecast by Type
      13.7.1. Hemophilia A
      13.7.2. Hemophilia B
      13.7.3. Hemophilia Gene Therap
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Hemophilia Gene Therapy Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Hemophilia Gene Therapy Market: Market Share Analysis
   14.2. Hemophilia Gene Therapy Distributors and Customers
   14.3. Hemophilia Gene Therapy Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Spark Therapeutics
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Ultragenyx
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Shire PLC
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Sangamo Therapeutics
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Bioverativ
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. BioMarin
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. uniQure
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Freeline Therapeutics
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Hemophilia Gene Therap
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us